Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
1.130
+0.110 (10.78%)
Jan 2, 2025, 4:00 PM EST - Market closed
Sangamo Therapeutics Employees
Sangamo Therapeutics had 405 employees as of December 31, 2023. The number of employees decreased by 73 or -15.27% compared to the previous year.
Employees
405
Change (1Y)
-73
Growth (1Y)
-15.27%
Revenue / Employee
$129,114
Profits / Employee
-$332,938
Market Cap
235.77M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
SGMO News
- 4 hours ago - Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - Business Wire
- 6 hours ago - Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
- 7 hours ago - Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
- 12 hours ago - Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation - Accesswire
- 2 days ago - Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Benzinga
- 2 days ago - Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact - Market Watch
- 2 days ago - Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact - Investopedia
- 2 days ago - Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact - Benzinga